Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/22/22 Free 111,193 0.2314%
1/19/21 Sell 1 0.0000%
1/19/21 Sell 2,000 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
-1.00%+4.43%+49.60%+1.42% 85.08B
-1.29%+4.27%+519.00%+32.26% 60.21B
-0.67%+1.20%-17.29%-35.03% 59.71B
-1.60%-7.34%-5.08%+31.05% 51.1B
+0.09%-0.54%+9.26%+165.71% 48.73B
+0.83%+1.36%+58.53%-15.97% 32.9B
-0.64%+0.20%+47.19%+97.87% 26.11B
+0.68%-3.81%+3.30%+199.71% 22.6B
+1.10%-1.67%+64.17%+118.01% 16.42B
Average -7.74%-0.26%+80.97%+66.12% 44.76B
Weighted average by Cap. -0.57%+0.72%+96.59%+44.97%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock